


Abb.1







Abb.2B






Abb. 2c

Abb.3






Abb. 4



DP178

Abb.5

A



B

NIH-Peptides	
6336	QREKRAAI GALFLGF
6337	RAAI GALFLGFLGAA
6338	GALFLGFLGAACTM
6339	LGFLGAACTMGAAS
6340	GAACTMGAASVTLT
6341	STMGAASTVTLTQAR
6342	AASVTLTQARLLS
6343	TLTQARLLSGI VO
6344	QARLLSGI VOQNN
6345	LLSGI VOQNNLLRA
DP107	NNLLRAI EAQQHLLQLTVNGI KQLQARI LAVERYKQDQ

Abb.6




Abb.7




Abb.8






Abb.9



12/16

Abb. 10

A: von gp41 abgeleitete rekombinante Proteine



B: von p15E/gp41 abgeleitete rekombinante Proteine





Abb. 11

A: Rekombinantes Loop-Protein



B: Freie Peptide und Peptide nach Cross-linking an 6kDa Dextran

mittels PDPH






Abb.12



16/16

Abb. 14 Neutralisierende Eigenschaften von Rattenseren nach Immunisierung mit Leucogen entweder mit dem rekombinanten p15E von FeLV(Gruppe 54) oder ohne diese Protein (Gruppe 56) dem

